Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
5.18
-0.27 (-4.95%)
Oct 10, 2025, 3:16 PM EDT - Market open

Company Description

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder.

It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD.

In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders.

ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Amstelveen, The Netherlands.

Atai Life Sciences N.V.
Atai Life Sciences logo
CountryNetherlands
Founded2018
IPO DateJun 18, 2021
IndustryBiotechnology
SectorHealthcare
Employees54
CEOSrinivas Rao

Contact Details

Address:
Prof. J.H. Bavincklaan 7
Amstelveen, 1183 AT
Netherlands
Phone31 20 793 2536
Websiteatai.com

Stock Details

Ticker SymbolATAI
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001840904
CUSIP NumberN0731H103
ISIN NumberNL0015000DX5
SIC Code2834

Key Executives

NamePosition
Dr. Srinivas G. Rao M.D., Ph.D.Co-Founder, Chief Executive Officer and Executive Director
Christian AngermayerCo-Founder and Chairman of the Supervisory Board
Anne JohnsonChief Financial Officer
Dr. Gerd G. Kochendoerfer Ph.D.Chief Operating Officer
Dr. Glenn Short Ph.D.Chief Scientific Officer
Ryan Barrett J.D.General Counsel and Corporate Secretary
Dr. Kevin Craig M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Sep 29, 2025S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuers
Sep 29, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 29, 20258-KCurrent Report
Sep 24, 2025DEFM14AFiling
Sep 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 23, 20258-KCurrent Report
Aug 18, 2025SCHEDULE 13D/AFiling
Aug 14, 202510-QQuarterly Report
Aug 14, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 14, 20258-KCurrent Report